Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson's disease patients
- 8 March 2022
- journal article
- research article
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 97, 84-90
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Open-Label Study Assessment of Safety and Adverse Effects of Subcutaneous Apomorphine Injections in Treating "Off" Episodes in Advanced Parkinson DiseaseClinical Neuropharmacology, 2009
- Intermittent Subcutaneous Apomorphine Therapy for ???Off??? Episodes in Parkinson??s DiseaseCNS Drugs, 2008
- Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single doseJournal of the Neurological Sciences, 2007
- Ultra-Fast Absorption of Amorphous Pure Drug Aerosols via Deep Lung InhalationJournal of Pharmaceutical Sciences, 2006
- Fast Onset Medications through Thermally Generated AerosolsThe Journal of Pharmacology and Experimental Therapeutics, 2004
- A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's diseaseMovement Disorders, 1996
- Transient atrial fibrillation after subcutaneous apomorphine bolusMovement Disorders, 1996
- Cardiac Arrhythmias and the Autonomic Nervous SystemJournal of Cardiovascular Electrophysiology, 1993
- Peripheral pharmacokinetics of apomorphine in humansAnnals of Neurology, 1989
- Clinical Observations on the Role of the Vegetative Nervous System in the Pathogenesis of Atrial FibrillationCardiology, 1958